AXDX 📈 Accelerate Diagnostics - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00430H1023

AXDX: Diagnostic Platform, Test Kits

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona. Web URL: https://acceleratediagnostics.com

Additional Sources for AXDX Stock

AXDX Stock Overview

Market Cap in USD 38m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Life Sciences Tools & Services
IPO / Inception 1996-11-18

AXDX Stock Ratings

Growth 5y -77.4%
Fundamental -18.5%
Dividend -
Rel. Strength Industry -2154
Analysts 5/5
Fair Price Momentum 0.45 USD
Fair Price DCF -

AXDX Dividends

No Dividends Paid

AXDX Growth Ratios

Growth Correlation 3m -73.8%
Growth Correlation 12m 42.7%
Growth Correlation 5y -96%
CAGR 5y -63.34%
CAGR/Mean DD 5y -0.83
Sharpe Ratio 12m -0.90
Alpha -114.74
Beta 1.72
Volatility 92.73%
Current Volume 384.8k
Average Volume 20d 86.2k
What is the price of AXDX stocks?
As of December 30, 2024, the stock is trading at USD 1.10 with a total of 384,762 shares traded.
Over the past week, the price has changed by +0.00%, over one month by -33.73%, over three months by -35.67% and over the past year by -71.94%.
Is Accelerate Diagnostics a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Accelerate Diagnostics is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -18.49 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AXDX as of December 2024 is 0.45. This means that AXDX is currently overvalued and has a potential downside of -59.09%.
Is AXDX a buy, sell or hold?
Accelerate Diagnostics has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy AXDX.
  • Strong Buy: 1
  • Buy: 0
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for AXDX stock price target?
According to ValueRays Forecast Model, AXDX Accelerate Diagnostics will be worth about 0.5 in December 2025. The stock is currently trading at 1.10. This means that the stock has a potential downside of -54.55%.
Issuer Forecast Upside
Wallstreet Target Price 1.5 36.4%
Analysts Target Price 9 718.2%
ValueRay Target Price 0.5 -54.5%